Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Teva Pharmaceutical Industries has completed its acquisition of Emalex Biosciences for $700 million upfront, with potential milestone payments up to $200 million. The acquisition adds ecopipam, a first-in-class D1 receptor antagonist for pediatric Tourette syndrome, to Teva's pipeline. Phase 3 data was recently published in JAMA Neurology showing statistical significance versus placebo, with an NDA submission anticipated in the second half of 2026.